Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trialHertzel C. Gerstein, Anselmo P. Bordonava, Helen M. Colhoun et al.|The Lancet|2019Cited by 3.1k
Impact of Regulatory Guidance on Evaluating Cardiovascular Risk of New Glucose-Lowering Therapies to Treat Type 2 Diabetes MellitusAbhinav Sharma, Christopher B. Granger, Jyothis T. George et al.|Circulation|2020Cited by 108
TRITON and Beyond: New Insights into the Profile of PrasugrelJoseph A. Jakubowski, David Erlinge, Jeffrey S. Riesmeyer et al.|Cardiovascular Therapeutics|2011Cited by 24